Document is current
Any future updates will be listed below
-
Authors
Agrawal, Manasi https://orcid.org/0000-0003-4729-1485
Midya, Vishal https://orcid.org/0000-0002-6643-5176
Vianello, Alvise https://orcid.org/0000-0001-6069-2625
Valvi, Damaskini
Kaplan, Gilaad G. https://orcid.org/0000-0003-2719-0556
Colombel, Jean-Frederic https://orcid.org/0000-0001-6472-249X
- License Information
-
More Information
Article History
Accepted: 4 September 2026
First Online: 18 September 2026
Ethics
Competing interests: M.A. has received payment for participation in Sanofi advisory board. V.M. is an adviser at Linus Biotechnology, a startup company affiliated with the Mount Sinai Health System. G.G.K. has received honoraria for speaking or consultancy from AbbVie, Amgen, Janssen, Pfizer and Takeda, and research grants from Ferring and for educational activities from AbbVie, Bristol Myers Squibb, Ferring, Fresenius-Kabi, Janssen, Pfizer and Takeda. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 Sept. 2018. J.-F.C. reports receiving research grants from AbbVie, Janssen Pharmaceuticals, Takeda, Prometheus and Bristol Myers Squibb; receiving payment for lectures from AbbVie, Roche and Takeda; receiving consulting fees from AbbVie, Amgen, AnaptysBio, Allergan, Apini, Arena Pharmaceuticals, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, candidrx, Celgene, Celltrion, Clearview Curogen, Eli Lilly, Envision Pharma, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Roche, Janssen Pharmaceuticals, Kaleido Biosciences, Immunic, Iterative Scopes, Landos, Microba Life Science, Merck, Mirador, Novartis, Otsuka Pharmaceutical, Owkin, Pfizer, Protagonist Therapeutics, Sanofi, Sun Pharma, Takeda, Teva and TiGenix; and is holding stock options in Intestinal Biotech Development. A.V. and D.V. declare no competing interests.
